Durvalumab and Tremelimumab

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Drug Information

Target Indication

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Related Pipeline

Irritable Bowel Syndrome With Constipation (IBS-C)

Muscle Invasive Bladder Cancer

Asthma, Exercise-Induced

Affective Psychosis, Bipolar

Carcinoma, Non-Small-Cell Lung